MEDICATION management company, MedAdvisor, is targeting global growth after reporting 20% year-on-year growth.
In a statement to the Australian Securities Exchange (ASX) MedAdvisor CEO, Robert Read, noted the business had seen "green shoots from initial revenues in the US", in the fourth quarter of the 2020 Financial Year.
The company reported a total Q4 FY2020 revenue of $4.4 million, a 99.8% increase on Q3 FY2020 revenues.
"MedAdvisor has delivered another record revenue quarter as we continue to deliver on our strategic priorities," he said.
"In Australia and around the world, pharmacists are at the coalface of the COVID-19 fight - we are making their lives simpler with easy-to-use digital tools that streamline their workflows and improve customer experience and loyalty."
MedAdvisor reported continued growth in the Australian market, with close to 1.7 million patients signed up to the platform.
The company told the ASX its on-demand home delivery service had processed more than 12,000 delivery requests and had seen more than 34,000 items ordered on the platform.
Internationally, MedAdvisor said its new strategic alliance with HMS was a highlight of the quarter.
"The HMS Eliza business has sent more than 865 million unique patient outreaches since 2016," MedAdvisor said.
"MedAdvisor will receive a revenue share for each of the secure digital messages that are sent.
"The new integration is expected to go live towards the end of Q2 FY2021."
The company said it had progressed initial marketing with the UK National Pharmacy Association for its pharmacy app, which is due to go live in Q2 FY2021.
MedAdvisor also told investors that it was on track to deliver revenue in Q1 FY2021 through its Asian joint venture with Zuellig Pharma, with the MedExpress App expected to go live in the first quarter.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Jul 20
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Jul 20
